argenx down 7% as FDA identifies possible safety signal with Vyvgart Hytrulo

1 week ago 2

• Healthcare
• On the Move

hapabapa

• argenx (NASDAQ:ARGX) is down ~7% in Monday trading after the U.S. FDA issued an alert on a potential signal of serious risks associated with Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase).
• The agency says that the treatment, used for generalized myasthenia gravis

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. argenx down 7% as FDA identifies possible safety signal with Vyvgart Hytrulo